Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Pfizer Inc. (ETR:PFE)
|Dividend Rate (ttm)||1.5500|
|Trading Day||Sep 21|
|Day's Range||37.55 - 39.785|
|52 Week Range||27.52 - 44.27|
NewsNo news found.
Pfizer Inc. dividends
Pfizer Inc. has a market cap or net worth of €210.53 billion. The enterprise value is €229.56 billion.
Pfizer Inc. has 5.61 billion shares outstanding.
The trailing PE ratio is 16.0291 and the forward PE ratio is 0.0000. Pfizer Inc.'s PEG ratio is -2.2403.
Stock Price Statistics
The stock price has increased by 0.2493%. The beta is 0.0000, so Pfizer Inc.'s price volatility has been lower than the market average.
In the last 12 months, Pfizer Inc. had revenue of €51.64 billion and earned €36.35 billion in profits. Earnings per share was €2.34.
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare.
It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare.
The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr.
and Charles Erhart in 1849 and is headquartered in New York, NY..